Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CA3 | P07451 | 2/20 | 0.59 |
| ▸ | CA5A | P35218 | 2/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | PGK1 | P00558 | 1/20 | 0.44 |
| ▸ | PGK2 | P07205 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7529344 | 0.94 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL13861685 | 0.87 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL10650040 | 0.86 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL4147505 | 0.86 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL16221898 | 0.85 | MEN1 (0.79) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL12334756 | 0.80 | EPHX1 (0.41) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL1252712 | 0.80 | CA3 (0.86) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL10231803 | 0.80 | CA3 (0.86) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL11895560 | 0.78 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL10223283 | 0.78 | POLB (0.44) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220242843-A1 | PROCESS FOR PREPARING A COUMARIN-CAGED FORSKOLIN DERIVATIVE, FORSKOLIN DERIVATIVE AND USE OF SAID FORSKOLIN DERIVATIVE | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2022-08-04 | — | — | US | claimed |
| EP-4003968-A1 | PROCESS FOR PREPARING A COUMARIN-CAGED FORSKOLIN DERIVATIVE, FORSKOLIN DERIVATIVE AND USE OF SAID FORSKOLIN DERIVATIVE | Forschungszentrum Jülich GmbH (DE) | 2022-06-01 | — | — | EP | claimed |
| CN-114096527-A | Method for preparing coumarin caged forskolin derivative, forskolin derivative and application of forskolin derivative | 于利奇研究中心有限公司 | 2022-02-25 | — | — | CN | claimed |
| WO-2021013278-A1 | PROCESS FOR PREPARING A COUMARIN-CAGED FORSKOLIN DERIVATIVE, FORSKOLIN DERIVATIVE AND USE OF SAID FORSKOLIN DERIVATIVE | Forschungszentrum Jülich GmbH (DE) | 2021-01-28 | — | — | WO | claimed |
| CN-114957163-B | Preparation method of N-methyl homopiperazine | 合肥亿帆生物制药有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-114957163-A | Preparation method of N-methyl homopiperazine | 合肥亿帆生物制药有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220242843-A1 | PROCESS FOR PREPARING A COUMARIN-CAGED FORSKOLIN DERIVATIVE, FORSKOLIN DERIVATIVE AND USE OF SAID FORSKOLIN DERIVATIVE | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2022-08-04 | — | — | US | disclosed |
| US-20220242843-A1 | PROCESS FOR PREPARING A COUMARIN-CAGED FORSKOLIN DERIVATIVE, FORSKOLIN DERIVATIVE AND USE OF SAID FORSKOLIN DERIVATIVE | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2022-08-04 | — | — | US | disclosed |
| EP-4003968-A1 | PROCESS FOR PREPARING A COUMARIN-CAGED FORSKOLIN DERIVATIVE, FORSKOLIN DERIVATIVE AND USE OF SAID FORSKOLIN DERIVATIVE | Forschungszentrum Jülich GmbH (DE) | 2022-06-01 | — | — | EP | disclosed |
| CN-114096527-A | Method for preparing coumarin caged forskolin derivative, forskolin derivative and application of forskolin derivative | 于利奇研究中心有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-20220033372-A1 | METHODS AND COMPOSITIONS RELATING TO GENOTOXIN COLIBACTIN | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-02-03 | — | — | US | disclosed |
| US-11040951-B2 | Methods and compositions relating to genotoxin colibactin | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-22 | — | — | US | disclosed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| US-20020016322-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use | NICOX S.A. (FR) | 2002-02-07 | — | — | US | disclosed |
| US-6297260-B1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED, INC. | 2001-10-02 | — | — | US | disclosed |
| EP-1132376-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2001-09-12 | — | — | EP | disclosed |
| EP-1126838-A1 | NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-2000025776-A1 | NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016322-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use | NOS2, NOS3, NOS1 | ALDH1A1 1076/4885SMN1; SMN2 2977/4885POLB 3012/4885 |
| US-20220242843-A1 | PROCESS FOR PREPARING A COUMARIN-CAGED FORSKOLIN DERIVATIVE, FORSKOLIN DERIVATIVE AND USE OF SAID FORSKOLIN DERIVATIVE | PCSK7, PCSK6, NISCH | ALDH1A1 2566/4885SMN1; SMN2 4504/4885POLB 3523/4885 |
| US-20220033372-A1 | METHODS AND COMPOSITIONS RELATING TO GENOTOXIN COLIBACTIN | CACYBP, MYCBP, CLSPN | ALDH1A1 4352/4885SMN1; SMN2 4730/4885POLB 63/4885 |
| US-11040951-B2 | Methods and compositions relating to genotoxin colibactin | CACYBP, MYCBP, CLSPN | ALDH1A1 4352/4885SMN1; SMN2 4730/4885POLB 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.